Regeneron Pharmaceuticals, Inc. $REGN Shares Newly Purchased by MBL Wealth LLC

MBL Wealth LLC acquired a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the 3rd quarter, Holdings Channel.com reports. The fund acquired 1,107 shares of the biopharmaceutical company’s stock, valued at approximately $839,000.

Other hedge funds have also bought and sold shares of the company. Brookstone Capital Management bought a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter worth approximately $212,000. Root Financial Partners LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter worth approximately $293,000. Reyes Financial Architecture Inc. bought a new position in Regeneron Pharmaceuticals during the 3rd quarter valued at approximately $106,000. Lmcg Investments LLC increased its position in Regeneron Pharmaceuticals by 2.4% during the 3rd quarter. Lmcg Investments LLC now owns 37,703 shares of the biopharmaceutical company’s stock valued at $28,589,000 after buying an additional 866 shares in the last quarter. Finally, Cardinal Capital Management increased its position in Regeneron Pharmaceuticals by 3.8% during the 3rd quarter. Cardinal Capital Management now owns 8,713 shares of the biopharmaceutical company’s stock valued at $6,607,000 after buying an additional 316 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Marion Mccourt sold 1,131 shares of the business’s stock in a transaction on Thursday, September 3rd. The stock was sold at an average price of $857.39, for a total value of $969,708.09. Following the completion of the transaction, the executive vice president owned 12,003 shares in the company, valued at $10,291,252.17. The trade was a 8.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the company’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total value of $340,000.00. Following the transaction, the director directly owned 603 shares in the company, valued at approximately $512,550. The trade was a 39.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 8,093 shares of company stock valued at $6,506,845. 6.97% of the stock is currently owned by company insiders.

Key Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: TD Cowen raised its price target to $980 from $960 while maintaining a positive view of Regeneron, signaling potential upside from current levels. TD Cowen raises target for Regeneron stock
• Positive Sentiment: Analysts and investors continue to point to Regeneron’s growth potential, including strong Dupixent performance and positive Phase 3 OPTIMA results for investigational pasatru in fibrodysplasia ossificans progressiva. The company is also working to build a broader global oncology business. Regeneron growth potential analysis
• Neutral Sentiment: Regeneron is scheduled to report quarterly results next week. Analysts expect earnings to grow, but the company reportedly lacks the typical combination of estimate revisions and other indicators associated with a likely earnings beat, creating uncertainty ahead of the release. Regeneron earnings expectations
• Neutral Sentiment: Recent coverage describes REGN as a relatively steady stock and notes that it gained in the prior session, although it lagged some competitors. This provides limited new information about the company’s fundamentals. Regeneron stock performance versus competitors
• Negative Sentiment: Valuation-related commentary asks whether Regeneron is priced too highly relative to pharmaceutical peers, which could limit near-term upside and encourage profit-taking ahead of earnings. Regeneron valuation versus rivals

Regeneron Pharmaceuticals Trading Down 1.7%

Shares of NASDAQ REGN opened at $805.02 on Friday. The firm’s 50 day moving average price is $791.86 and its 200-day moving average price is $723.16. Regeneron Pharmaceuticals, Inc. has a 52-week low of $575.93 and a 52-week high of $859.34. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.78 and a current ratio of 3.34. The company has a market cap of $82.88 billion, a PE ratio of 19.90, a P/E/G ratio of 1.38 and a beta of 0.16.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, beating the consensus estimate of $10.16 by $4.13. The company had revenue of $4.29 billion during the quarter, compared to the consensus estimate of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The firm’s quarterly revenue was up 16.7% compared to the same quarter last year. During the same quarter last year, the firm earned $12.81 earnings per share. On average, equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 49.10 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th were paid a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a yield of 0.5%. The ex-dividend date was Tuesday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 9.29%.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. Raymond James Financial lifted their price objective on Regeneron Pharmaceuticals from $902.00 to $911.00 and gave the company an “outperform” rating in a research note on Friday, July 31st. Zacks Research raised Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, September 28th. Weiss Ratings reissued a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research note on Monday, September 21st. Argus upgraded Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $850.00 price target for the company in a report on Thursday, October 1st. Finally, Piper Sandler lifted their price target on Regeneron Pharmaceuticals from $854.00 to $865.00 and gave the stock an “overweight” rating in a research report on Monday, October 19th. One analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $846.28.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.